Vioxx

(rofecoxib)

ApprovedSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Vioxx is one of 129 small molecule programs targeting Headache. It is currently in Approved.

Indications

Total Trials

Active Trials

128

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Prostate CancerActive, not recruiting

OsteoarthritisActive, not recruiting

SprainActive, not recruiting

GrowthActive, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

OsteoarthritisPhase 3

Active, not recruiting

SprainApproved

Active, not recruiting

GrowthPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Vioxx

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 9

Prednisone/prednisolone

Roche

Preclinical

3 10

Triptorelin Pamoate

Ipsen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis2 trials

A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee

Completed·JJohnson & Johnson Consumer and Personal Products Worldwide·Phase 3·NCT00568295·403 enrolled

Safety of Lumiracoxib in Patients With Osteoarthritis

Completed· Novartis logo

Novartis·Phase 3·NCT00637949·309 enrolled

Colorectal Cancer1 trial

Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer

Completed·CCancer Research Campaign Clinical Trials Centre·Phase 3·NCT00031863

Headache1 trial

An End to the Yom Kippur (and Ramadan) Headache

Completed·SSheba Medical Center·N/A·NCT00263094·220 enrolled

Prostate Cancer1 trial

Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00060476·15,000 enrolled

Alzheimer's Disease1 trial

A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)

Completed·NNational Institute on Aging (NIA)·Phase 2/3·NCT00004845

6 more indications

Growth1 trial

Coxib-inhibition of Duodenal Polyp Growth in FAP

Terminated·OOslo University Hospital·Phase 2/3·NCT00844727·38 enrolled

Sprain1 trial

A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

Terminated· Pfizer logo

Pfizer·Phase 4·NCT00657449·45 enrolled

Acetaminophen1 trial

CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen

Completed·HHospital Universitario Pedro Ernesto·N/A·NCT01762891·22 enrolled

Third Molar1 trial

Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction

Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00026819·150 enrolled

Barrett's esophagus1 trial

Barrett's Esophagus - 315 - 3 Way Cross Over

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00637988·32 enrolled

Advanced NSCLC1 trial

Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC

Completed·NNational Cancer Institute, Naples·Phase 2/3·NCT00385606·400 enrolled

Regulatory

FDA Approval Timeline[4]

May 20, 1999

VIOXX

NDA NDA021052

May 20, 1999

VIOXX

NDA NDA021042

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for rofecoxib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rofecoxib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rofecoxib. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021052). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Vioxx

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis2 trials

Colorectal Cancer1 trial

Headache1 trial

Prostate Cancer1 trial

Alzheimer's Disease1 trial

Growth1 trial

Sprain1 trial

Acetaminophen1 trial

Third Molar1 trial

Barrett's esophagus1 trial

Advanced NSCLC1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News